Cannabis

There are over 100+ unexplored cannabinoids in medicine

Latest News

cannabis
Psychiatry’s Risky Gamble on Recreational Drugs: The Royal Road to the Unconscious or Down a Pharmacologic Garden Path

September 12th 2024

Psychedelics: we first must enlarge our knowledge of how these work, what clinical conditions should be targeted, and how different psychedelics compare to each other.

alcohol cannabis
Addressing Alcohol or Cannabis Use in Patients With Anxiety Disorders

August 22nd 2024

cannabis
Not Your Average Hazard: Cannabis Use, Psychosis, and the Youthful Brain

August 21st 2024

cannabis
A Brief Cannabis Cessation Protocol to Increase Patient Motivation

June 20th 2024

cannabis
Cannabis Facts by State

June 11th 2024

Video Interviews
Podcasts
Latest CME Events & Activities

2023 Annual Psychiatric Times™ World CME Conference

View More

5th Annual International Congress on the Future of Neurology®

View More

Clinical Consultations™: Managing Depressive Episodes in Patients with Bipolar Disorder Type II

View More

Medical Crossfire®: Understanding the Advances in Bipolar Disease Treatment—A Comprehensive Look at Treatment Selection Strategies

View More

Patient, Provider, and Caregiver Connection™: Exploring Unmet Needs In Postpartum Depression – Making the Case for Early Detection and Novel Treatments

View More

'REEL’ Time Patient Counseling: The Diagnostic and Treatment Journey for Patients With Bipolar Disorder Type II – From Primary to Specialty Care

View More

Real Psychiatry 2025

January 17 - 18, 2025

View More

More Than ‘Blue’ After Birth: Managing Diagnosis and Treatment of Post-Partum Depression

View More

Patient, Provider & Caregiver Connection™: Reducing the Burden of Parkinson Disease Psychosis with Personalized Management Plans

View More

Expert Perspectives in the Recognition and Management of Postpartum Depression

View More

Southern California Psychiatry Conference

July 11-12, 2025

Register Now!

SimulatED™: Diagnosing and Treating Alzheimer’s Disease in the Modern Era

View More

Expert Illustrations & Commentaries™: New Targets for Treatment in Cognitive Impairment in Schizophrenia – The Role of NMDA Receptors and Co-agonists

View More

BURST CME™ Part I: Understanding the Impact of Huntington’s Disease

View More

Burst CME™ Part II: The Evolving Treatment Landscape for Huntington Disease

View More

Clinical ShowCase: Developing a Personalized Treatment Plan for a Patient with Huntington’s Disease Associated Chorea

View More

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

View More

Community Practice Connections™: Optimizing the Management of Tardive Dyskinesia—Addressing the Complexity of Care With Targeted Treatment

View More

PER Psych Summit: Integrating Shared Decision-Making Into Management Plans for Patients With Schizophrenia

View More

More News

© 2024 MJH Life Sciences

All rights reserved.